Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
about
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
description
im April 2019 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 05 April 2019
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2019
@uk
name
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@en
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@nl
type
label
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@en
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@nl
prefLabel
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@en
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@nl
P2093
P50
P1433
P1476
Octreotide-LAR in later-stage ...... -controlled, multicenter trial
@en
P2093
ALADIN 2 Study Group
Alessandro Villa
Antonio Granata
Antonio Pisani
Eleonora Riccio
Fabiola Carrara
Michele Figuera
Nadia Rubis
Norberto Perico
Sandro Sironi
P304
P356
10.1371/JOURNAL.PMED.1002777
P407
P50
P577
2019-04-05T00:00:00Z